诱饵
受体
病毒进入
血管紧张素转化酶2
冠状病毒
生物
病毒学
2019年冠状病毒病(COVID-19)
病毒
医学
病毒复制
生物化学
内科学
疾病
传染病(医学专业)
作者
Takao Arimori,Nariko Ikemura,Tomoyoshi Okamoto,Junichi Takagi,Daron M. Standley,Atsushi Hoshino
标识
DOI:10.1016/j.tips.2022.06.011
摘要
Decoy receptor proteins that trick viruses to bind to them should be resistant to viral escape because viruses that require entry receptors cannot help but bind decoy receptors. Angiotensin-converting enzyme 2 (ACE2) is the major receptor for coronavirus cell entry. Recombinant soluble ACE2 was previously developed as a biologic against acute respiratory distress syndrome (ARDS) and verified to be safe in clinical studies. The emergence of COVID-19 reignited interest in soluble ACE2 as a potential broad-spectrum decoy receptor against coronaviruses. In this review, we summarize recent developments in preclinical studies using various high-affinity mutagenesis and Fc fusion approaches to achieve therapeutic efficacy of recombinant ACE2 decoy receptor against coronaviruses. We also highlight the relevance of stimulating effector immune cells through Fc-receptor engagement and the potential of using liquid aerosol delivery of ACE2 decoy receptors for defense against ACE2-utilizing coronaviruses.
科研通智能强力驱动
Strongly Powered by AbleSci AI